Avinger Secures 510(k) Clearance For Pantheris LV Image-Guided Atherectomy System
Portfolio Pulse from Benzinga Newsdesk
Avinger has received FDA 510(k) clearance for its next-generation Pantheris LV image-guided atherectomy system, designed for the treatment of peripheral artery disease (PAD).
June 07, 2023 | 12:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Avinger's FDA 510(k) clearance for Pantheris LV may lead to increased sales and market share in the PAD treatment sector.
Avinger's FDA 510(k) clearance for Pantheris LV is a significant milestone for the company, as it allows them to market and sell the product in the US. This clearance may lead to increased sales and market share in the PAD treatment sector, as the product offers a next-generation solution for treating the condition. The news is highly relevant and important for investors, as it directly impacts the company's growth potential and revenue generation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100